, Volume 30, Issue 9, pp 1302-1304
Date: 26 Jul 2003

[Tc(CO)3]+ chemistry: a promising new concept for SPECT?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

In this commentary we will discuss some of the reasons why the [Tc(CO)3]+ approach to technetium radiopharmaceuticals has not obtained a place in the commercial arena. We do not disagree with the chemical achievements that were made in preparing bioactive technetium-labeled molecules utilizing the [Tc(CO)3]+ or [Re(CO)3]+ approach. For example, it is almost a decade since this approach was used in the synthesis of rhenium-labeled estrogen derivatives with high affinity for the estrogen receptor [1, 2]. One of us was a co-investigator on the evaluation of a technetium-labeled octreotide compound [3]. This agent showed specific uptake in tissues containing elevated levels of somatostatin receptors. As stated in the conclusion of this article, it also possessed other key features of an imaging agent, namely in vivo stability, retention by target tissues and low background accumulation in non-target tissues. Many receptor-specific agents have been labeled utilizing the [Tc(CO)3]+ or [Re(CO

The opinions expressed within the Controversies section represent the views of the authors only.